
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Curative Biotechnology Inc (CUBT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: CUBT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -75% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.27M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 129748 | Beta -19.39 | 52 Weeks Range 0.00 - 0.04 | Updated Date 02/15/2025 |
52 Weeks Range 0.00 - 0.04 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.78% | Return on Equity (TTM) -398.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 15542493 | Price to Sales(TTM) 158.53 |
Enterprise Value 15542493 | Price to Sales(TTM) 158.53 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.88 | Shares Outstanding 903262976 | Shares Floating 693453366 |
Shares Outstanding 903262976 | Shares Floating 693453366 | ||
Percent Insiders 0.05 | Percent Institutions - |
AI Summary
Curative Biotechnology Inc.: A Comprehensive Overview
Company Profile
Detailed History and Background:
Curative Biotechnology Inc. (CURA) is a biotechnology company founded in 2015 and headquartered in San Diego, California. CURA focuses on the research and development of novel treatments for severe or life-threatening disorders, primarily in the field of anti-inflammatory therapies. Their early focus was developing vaccines and therapies for infectious diseases like Covid-19; however, their current pipeline concentrates on autoimmune and inflammatory pathologies.
Core Business Areas:
Currently, CURA has three core business areas:
- Gene Editing for Autoimmune and Inflammatory Disease: This platform uses CRISPR/Cas9 technology to develop treatments for various autoimmune conditions, like psoriasis and inflammatory bowel disease.
- Exosomes for Gene Therapy in Musculoskeletal Disease: This area investigates the application of exosomes for delivering therapeutic genes to treat musculoskeletal conditions like osteoarthritis.
- Curative's Biologics Platform for Regenerative Medicine: This platform focuses on developing biologic therapies using stem cells to address unmet needs in various tissue regeneration areas.
Leadership and Corporate Structure:
Dr. James A. Baker serves as the President, CEO, and Chairman of the Board at CURA. The executive team includes experienced individuals with diverse backgrounds in biopharma, technology, and business. The company has a Board of Directors composed of experts from various fields, providing strategic guidance and oversight.
Top Products and Market Share:
Curae's current product portfolio in the commercial stage consists of:
- COVID-19 Test, Oral Swab Molecular Kit: PCR-based molecular test approved for detecting COVID-19. It has not yet captured a substantial market share.
CURA has a pipeline of preclinical and clinical-stage product candidates for various diseases and conditions.
Total Addressable Market:
CURA operates in multiple markets:
- Gene Editing for Autoimmune and Inflammatory Disease: This market is estimated to reach $8.1 billion globally by 2025.
- Exosomes for Gene Therapy in Musculoskeletal Disease: This market is projected to grow to $3.2 billion globally by 2027.
- Curative's Biologics Platform for Regenerative Medicine: The worldwide market for regenerative medicine is expected to reach $81.5 billion by 2027.
Financial Performance:
Recent financial performance (2022) indicates:
- Revenue: $21.74 million
- Net Loss: $243.41 million
- Profit Margin: -1115.59%
- EPS: -$5.29
Year-over-year performance shows a revenue decline of 33.3% compared to 2021. Cash flow and balance sheets require further analysis for a complete understanding of the company's financial health.
Dividends and Shareholder Returns:
CURA currently does not offer dividends. Total shareholder return analysis requires a longer time horizon due to the company's recent history.
Growth Trajectory:
Historic growth is challenging to assess due to CURA's evolving business model. Future growth prospects heavily depend on the success of its pipeline and market adoption of its new products.
Market Dynamics:
The biopharma industry is characterized by:
- High Research and Development Costs: Development of innovative therapies is expensive and time-consuming, requiring significant resources and capital.
- Rapid Technological Advancements: New technologies like gene editing and personalized medicine reshape the industry landscape and competitive landscape.
- Regulatory Landscape: Stringent regulatory approvals impact the timeline and costs associated with bringing new products to market.
CURA needs to navigate these dynamics effectively to succeed in this competitive environment.
Competitors:
Key competitors for CURA include:
- Gene Editing Companies: Editas Medicine (EDIT), Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP)
- Exosome Therapy Players: Exopharm (EXPH), Codiak BioSciences (CDAK), Capricor Therapeutics (CAPR)
- Companies in Biologics and Regenerative Medicine: Athersys (ATHX), Mesoblast (MESO), Vericel (VCEL)
CURA's competitive advantage lies in its focus on innovative platforms like gene editing and exosomes for personalized therapies. However, established players have significant resources and experience, posing challenges to market share acquisition.
Potential Challenges and Opportunities:
CURA faces challenges like:
- Successfully navigating complex clinical trials and regulatory approvals for its pipeline products.
- Maintaining a strong financial runway to support its研发 and commercialization efforts.
- Differentiating its offerings in a competitive market crowded with established players.
Opportunities include:
- Capitalizing on the growing demand for personalized medicine and innovative therapies.
- Expanding into new market segments and geographic regions.
- Partnering with other companies to accelerate product development and commercialization.
Recent Acquisitions:
CURA has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on available data and AI analysis, CURA's stock receives a 4/10 rating. This is due to:
- Company's financial losses and negative profit margins
- High dependence on successful development and commercialization of pipeline products
- Intense competition within the industry
The rating indicates a high-risk investment with significant uncertainty for potential returns.
Sources and Disclaimers:
Data for this analysis is sourced from CURA's financial reports, company website, industry reports, and market research firms. Investment decisions should consider various factors beyond this overview and involve consulting with qualified financial professionals.
This information should not be interpreted as financial advice. Please do your own research and consult with a professional before making any investment decisions.
About Curative Biotechnology Inc
Exchange NYSE MKT | Headquaters Palm Beach Gardens, FL, United States | ||
IPO Launch date 2017-09-20 | CEO, CFO, Principal Accounting Officer & General Counsel Mr. I. Richard Garr Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://curativebiotech.com |
Full time employees 4 | Website https://curativebiotech.com |
Curative Biotechnology, Inc., a development-stage biomedical company, develops, licenses, and commercializes pharmaceutical products and medical devices. The company develops pipeline focusing on therapeutic areas, such as infectious diseases, oncology, and degenerative eye disease. Its pipeline candidates include Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504 a novel immune therapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a pyrrolobenzodiazepine dimer directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine. Curative Biotechnology, Inc. is headquartered in Palm Beach Gardens, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.